A detailed history of Jane Street Group, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 50,221 shares of CRVS stock, worth $241,060. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,221
Holding current value
$241,060
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.78 - $5.92 $89,393 - $297,308
50,221 New
50,221 $265,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $24,942 - $44,342
23,095 New
23,095 $40,000
Q2 2023

Aug 14, 2023

BUY
$1.0 - $3.86 $35,118 - $135,555
35,118 New
35,118 $80,000
Q3 2022

Nov 14, 2022

BUY
$0.71 - $1.17 $14,750 - $24,306
20,775 New
20,775 $17,000
Q3 2021

Nov 16, 2021

BUY
$1.89 - $8.53 $328,740 - $1.48 Million
173,937 New
173,937 $842,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.